GlaxoSmithKline PLC
LSE:GSK
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 300
1 797.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
GlaxoSmithKline PLC
GlaxoSmithKline PLC
Cash Equivalents
GlaxoSmithKline PLC
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash Equivalents
£3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash Equivalents
$6.9B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash Equivalents
$336m
|
CAGR 3-Years
26%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash Equivalents
$302m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
39%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash Equivalents
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
Glance View
GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for investors. In recent years, GSK has taken strategic steps to simplify its business model, including the spin-off of its consumer healthcare segment into a separate entity. This maneuver has allowed GSK to concentrate on its core pharmaceutical and vaccine operations, optimizing its resources towards high-growth areas. As the world faces ongoing health crises and the demand for vaccines, particularly following the COVID-19 pandemic, GSK is well-positioned to capitalize on its innovation and solid market presence. For investors, GSK's balance sheet reflects a stable dividend, attractive growth prospects, and a commitment to sustainable practices, fostering confidence that it remains a compelling choice in the ever-evolving healthcare landscape.
See Also
What is GlaxoSmithKline PLC's Cash Equivalents?
Cash Equivalents
3B
GBP
Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Cash Equivalents amounts to 3B GBP.
What is GlaxoSmithKline PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-1%
Over the last year, the Cash Equivalents growth was -6%. The average annual Cash Equivalents growth rates for GlaxoSmithKline PLC have been -5% over the past three years , -6% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
